Briciclib

DB12004InvestigationalSmall molecule

Briciclib has been used in trials studying the treatment of Lymphoma, Neoplasms, Advanced Solid Tumor, and Acute Lymphocytic Leukemia.

Mechanism: Pharmacologically active on G1/S-specific cyclin-D1
Curator reviewed
Formula / weight: C₁₉H₂₃O₁₀PS · 474.42 g/mol (avg)
Code names: ON-014185

Resolves to

Compound

Structure

InChIKeyLXENKEWVEVKKGV-BQYQJAHWSA-NSMILESCOC1=CC(OC)=C(\C=C\S(=O)(=O)CC2=CC=C(OC)C(OP(O)(O)=O)=C2)C(OC)=C1

Targets

What you can answer from here — as of September 19, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Briciclib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.